'Autonomy with bridges': The chief architect of the Alexion buyout is now headed over to take command. Here's what he's thinking
AstraZeneca CEO Pascal Soriot has made it clear that he has a lot more in mind for newly purchased Alexion than soaking up the franchise drug side of the business and adding it to the pharma giant’s revenue stream — while chopping costs down to pay for the deal. And now he’s putting one of the chief architects of the deal in place as the new CEO of Alexion.
The Big Pharma announced this morning that it’s executing a trade of sorts between the teams of the two companies. Subject to a formal closure of the deal, sanctioned by the FTC now, Soriot is sending his CFO Marc Dunoyer over to the Boston company while taking Alexion CFO Aradhana Sarin as the new numbers chief at AstraZeneca.
Dunoyer also becomes AstraZeneca’s chief strategy officer, giving him a big role in the deals to come.
I spoke with Dunoyer about the Alexion deal a few weeks ago, ahead of this executive suite shakeup. In a closely focused conversation, Dunoyer explained how AstraZeneca narrowed a wide-ranging M&A search down to Alexion, offering some insights on the role Alexion will play as the company’s new center for rare diseases. What follows is the Q&A we had, edited for length and clarity.
I started by asking how AstraZeneca decided to go after Alexion.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.